youtube_live
Q3 2026 earnings • released • Revenue beat +15.81%
See resultschevron_right
4519:TYO
Chugai Pharmaceutical Co Ltd
¥6,614.00
arrow_downward
-1.11%(-74.00) 1D
Oct 28, 3:30:00 PM GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4519...
Open
¥6,788
High
¥6,844
Low
¥6,614
Mkt. cap
11.11T
Avg. vol.
3.36M
Volume
3.54M
Dividend
2.09%
Quarterly dividend
¥34
Ex-dividend date
Jun 29, 2026
P/E ratio
23.09
52-wk high
¥10,700
52-wk low
¥5,974
EPS
¥286
Shares outstanding
547.19M
No. of employees
5K
Open
¥6,788
High
¥6,844
Low
¥6,614
Mkt. cap
11.11T
Avg. vol.
3.36M
Volume
3.54M
Dividend
2.09%
Quarterly dividend
¥34
Ex-dividend date
Jun 29, 2026
P/E ratio
23.09
52-wk high
¥10,700
52-wk low
¥5,974
EPS
¥286
Shares outstanding
547.19M
No. of employees
5K
News stories
From web sources and news partners
TradingView
·
22 hours ago
Chugai Pharmaceutical : Revenue and profit advanced; full-year results are expected to exceed forecast
Investing.com
·
1 day ago
Chugai Q3 2026 slides: revenue up 17%, pipeline advances
finance.biggo.com
·
1 day ago
【Chugai Pharmaceutical FY2026 Q3 Earnings Call】Japan's Chugai Pharmaceutical Posts Q3 Revenue of ¥1.0681 Trillion, Up 17.2%, on Track to Beat Full-Year Guidance — Divarasib Shows PFS and OS Superiority Over First-Generation KRAS Inhibitors
Investing.com
·
1 day ago
Earnings call transcript: Chugai Pharmaceutical posts strong Q3 2026, shares slip
Profile
Chugai Pharmaceutical Co., Ltd. is a drug manufacturer operating in Japan. It is a subsidiary controlled by Hoffmann-La Roche, which owns 62% of the company as of 30 June 2014. The company is headquartered in Tokyo. Osamu Nagayama is the current representative director and chairman. Tatsuro Kosaka is the current representative director, president and CEO. Wikipedia
About Chugai Pharmaceutical Co Ltd
CEOOsamu Okuda
Employees5.1K
FoundedMar 10, 1925
Headquarters-
SectorPharmaceutical industry
Websitechugai-pharm.co.jp